ZNFTS
Zinc-dependent thymic hormone essential for T-cell maturation. Declines significantly with age.
3 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Thymulin (Zn-FTS) is a compound studied only in animals and lab experiments so far. Zinc-dependent thymic hormone essential for T-cell maturation.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published human dosing detailsAnimal models (lung inflammation, neuropathic pain) and adenoviral gene-therapy delivery of the analog metFTS; no published human dosing studies foundCommunity-reportedCommunity-reported: Research varies, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a zinc-dependent thymus hormone linked to T-cell development, mostly from animal studies. Requires zinc for activity. Described in reviews as involved in T-cell differentiation, with anti-inflammatory and analgesic properties reported for thymulin and a synthetic analogue, mainly in animal studies (Reggiani 2014; Safieh-Garabedian 2019).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedIn user communities, reported doses vary widely (subcutaneous injection). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Thymulin (Zn-FTS) | Unknown | Subcutaneous injection | Preclinical (animal) |
| Cerebrolysin | No published PK data found | IV or IM injection | Approved outside US |
| Cortexin | No published PK data found | Intramuscular injection | Approved outside US |
| Oxytocin | 3-5 minutes (but effects longer) | Intranasal | FDA-approved |
| VIP (Vasoactive Intestinal Peptide) | ~2 minutes | Intranasal or subcutaneous | Phase 3 |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Research category. View All Research Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.